Medical Oncologist
Targeted therapy
FGFR Alterations in Bladder and Bile Duct Cancer — and the Drugs That Target Them
If your tumour testing has found an FGFR mutation or fusion, a class of targeted drugs called FGFR inhibitors may be relevant to your treatment. Whether one is right for you depends on the specific type of alteration found and your cancer type.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Not all FGFR alterations are the same — Mutations, fusions, and amplifications each behave differently — the type of change found is what decides which drug, if any, applies to you.
- Two cancers are most commonly affected — FGFR3 alterations are a common molecular finding in bladder cancer; FGFR2 fusions are the key finding in bile duct cancer (cholangiocarcinoma).
- FGFR inhibitors are a targeted drug class — Several FGFR inhibitors have been approved internationally. Your oncologist will confirm which are accessible in India for your specific alteration.
- Side effects are specific to this class — FGFR inhibitors affect phosphate levels in the blood and can affect the eyes — your team will monitor both throughout treatment.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
FGFR mutations, fusions, and amplifications in bladder and bile duct cancer can be targeted with FGFR inhibitor drugs. Whether one applies to you depends on the specific alteration found in your tumour tissue. The same cancer type in two people can have different molecular profiles — your testing result is what determines the answer.
What are FGFR alterations, and which drugs target them?
FGFR stands for Fibroblast Growth Factor Receptor. When FGFR is altered — through a mutation in the gene, a fusion with another gene, or amplification — it can send constant signals that drive cancer cells to grow and divide.
In bladder cancer, FGFR3 alterations (mutations and fusions) are among the more common molecular findings. In bile duct cancer — known medically as intrahepatic cholangiocarcinoma — FGFR2 fusions and rearrangements are the most clinically relevant alteration.
Several FGFR inhibitors have been approved by regulatory bodies including the FDA and EMA. Erdafitinib is approved for bladder cancer with certain FGFR3 mutations or fusions. Pemigatinib and futibatinib are each approved for bile duct cancer with FGFR2 fusions or rearrangements. Availability and approval in India is determined by CDSCO — your oncologist can confirm which are currently accessible.
Not every FGFR alteration predicts response to every FGFR inhibitor. The type of alteration — mutation, fusion, or amplification — determines whether a drug in this class is likely to help.
What happens from the time your FGFR result comes back?
Result review
Your oncologist goes through the molecular testing report with you, explains what alteration was found, and whether it is one with an available targeted treatment.
Multidisciplinary discussion
For bladder and bile duct cancers with FGFR alterations, the result is typically discussed at a tumour board before a treatment plan is confirmed.
Treatment decision
Your oncologist recommends whether an FGFR inhibitor is indicated, at what point in your treatment course, and whether it would be used alone or alongside other therapies.
Baseline assessments
Before starting, you will have blood tests including phosphate levels and a baseline eye examination — the two areas FGFR inhibitors most commonly affect.
Starting the drug
FGFR inhibitors are oral medications taken at home on a schedule your team will explain. You will receive a written guide on side effects and when to call.
Ongoing monitoring
Regular blood tests and eye checks continue throughout treatment. Most dose adjustments happen in the early weeks as your team finds the right level for you.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What side effects do FGFR inhibitors cause?
The most distinctive side effect of FGFR inhibitors is raised phosphate in the blood, called hyperphosphataemia. FGFR signalling normally helps the kidneys manage phosphate — blocking it changes this balance, and your team will check phosphate levels regularly throughout treatment.
Eye problems are also associated with this drug class. These range from dry eyes and blurred vision to more significant changes including effects on the retina. Tell your team immediately if you notice any change in your vision — do not wait for your next scheduled appointment.
Other common side effects include fatigue, mouth sores, diarrhoea, nail changes, and skin changes. Most are manageable with dose adjustments, supportive medicines, or both.
Not everyone experiences every side effect, and many people tolerate FGFR inhibitors without significant disruption to daily activities. Your team will give you a specific list of what to watch for and clear instructions on when to call.
What should you tell your team while you are on this treatment?
Tell your team before you start any new medicine, supplement, or herbal preparation. Several commonly used medications interact with FGFR inhibitors and may need to be adjusted.
Report any change in your vision as soon as you notice it. Eye effects from FGFR inhibitors are more manageable when caught early and can become more serious if left unreported.
If you have been advised to follow a low-phosphate diet for any reason — such as a kidney condition — tell your team before starting treatment, because your dietary plan may need to change.
Bring the name and dose of every medicine you take to each appointment, including anything bought over the counter and any traditional or Ayurvedic preparations. Some combinations need to be managed carefully, and this is not a formality.
Other questions about FGFR-targeted therapy
Can an FGFR inhibitor be used in any cancer that shows an FGFR alteration?
No, and this is an important distinction. Approvals for FGFR inhibitors are specific to both the cancer type and the alteration type. Erdafitinib's approval, for example, is for bladder cancer with specific FGFR3 changes — it is not automatically indicated for an FGFR3 change found in a different cancer. Your oncologist will check whether the combination of your cancer type and your specific alteration matches an approved or clinically supported indication before recommending this class of drug.
What is the difference between an FGFR mutation, a fusion, and an amplification?
These are three different types of molecular change, and each responds differently to available drugs. A mutation is an alteration in the FGFR gene's own sequence that changes how the protein it produces behaves. A fusion is when part of the FGFR gene joins with part of another gene, creating an abnormal combined protein. An amplification means the gene is present in too many copies, driving overproduction of the FGFR protein. This is why the specific alteration type matters — not just the fact that FGFR is mentioned on your report.
Does having an FGFR alteration mean immunotherapy will not work?
Not necessarily, but the relationship is not straightforward. In bladder cancer, high FGFR3 alteration is sometimes associated with molecular features that influence how likely immunotherapy is to help. In bile duct cancer, the picture is different again. Your oncologist will look at your full molecular profile — including PD-L1 expression, microsatellite instability status, and tumour mutational burden as reported by NCCN and ESMO guidance — before deciding on sequence or combination. The two approaches are not automatically mutually exclusive.
What happens if the FGFR inhibitor stops working?
Cancers can develop ways to bypass FGFR inhibition over time. If your disease progresses while on an FGFR inhibitor, your oncologist will discuss further testing to understand how the cancer has changed and consider other options based on what the new results show. In some cases, re-testing of the tumour at the time of progression identifies new molecular changes that can guide the next treatment. NCCN and ESMO guidance for both bladder and bile duct cancers includes recommendations for treatment after a targeted therapy has stopped working.
How do we access an FGFR inhibitor in India?
CDSCO approval for specific FGFR inhibitors in India may differ from what is approved in the US or Europe. Some drugs are available through named-patient or compassionate use processes; others may be accessible through clinical trials. Your oncologist is the right person to advise on what is currently available, what the cost looks like in indicative terms — noting that figures change and vary by route of access — and whether any assistance programmes apply to your situation. We do not quote drug costs on this page because they change and depend on how the drug is sourced.
We have been told this is a rare finding. Should we get a second opinion?
Seeking a second opinion on a rare or complex molecular finding is a reasonable and appropriate step. A second review of your molecular testing report by another oncologist with experience in your cancer type can confirm the interpretation and whether the proposed treatment plan is consistent with current guidance from bodies such as NCCN or ESMO. Ask your team for the testing report in writing — any second-opinion centre will need it, and the original tumour tissue may need to be available if re-testing is recommended.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How do I know if my tumour has been tested for FGFR?
Ask your oncologist for a copy of your molecular testing report and check whether FGFR2 and FGFR3 are listed. Standard next-generation sequencing panels used in most major centres include FGFR alterations, but not all panels cover all types — fusions are sometimes missed by panels that detect mutations only. If you have bladder cancer or bile duct cancer and testing has not been done, or if the report is unclear, ask specifically whether your result covers FGFR2 and FGFR3 fusions as well as mutations.
My report says FGFR3 amplification — is that the same as a mutation?
No. Amplification means the gene is present in too many copies, which is different from a point mutation that changes the gene's sequence or a fusion that joins it to another gene. Amplification is generally less predictive of response to current FGFR inhibitors than mutations or fusions. Share the exact wording of your report with your oncologist, because the specific finding — not just the fact that FGFR3 is mentioned — determines whether a targeted drug applies to you.
Is this a first-line treatment or something used later?
It depends on the cancer and the specific clinical situation. For bladder cancer, erdafitinib is currently indicated after prior platinum-based chemotherapy. For bile duct cancer, pemigatinib and futibatinib are indicated after at least one prior line of treatment. Guidance continues to evolve as clinical trial data matures, and your oncologist will explain where in your treatment sequence an FGFR inhibitor fits and whether earlier use is available through a trial.
Can I still work and travel while taking an FGFR inhibitor?
Many people continue working and daily activities on FGFR inhibitors, particularly once the early dose-adjustment weeks have settled. Travel within India is generally manageable if monitoring appointments and access to urgent review are planned around longer trips. Eye effects and fatigue affect some people more than others. Ask your team for a realistic picture based on your individual situation — the first few weeks on a new targeted therapy often require more flexibility than later in the course.
We saw FGFR inhibitors mentioned alongside CAR-T therapy. Are these related?
No, they are completely different treatments. FGFR inhibitors are small-molecule drugs that block the FGFR protein's activity and are taken as oral tablets at home. CAR-T therapy is a cell therapy involving modification of a person's own immune cells outside the body. CION does not provide CAR-T or cell therapy. If CAR-T has been suggested for your situation, your oncologist can refer you to a centre that offers it.
What questions should I bring to my next appointment?
Ask your oncologist to identify the specific FGFR alteration on your molecular report and explain what type it is — mutation, fusion, or amplification. Ask whether that specific type matches an approved indication for an FGFR inhibitor, and if so, at what point in your treatment it would be considered. Ask about the monitoring schedule for phosphate levels and eye checks. If access or cost is a concern, ask what is currently available in India and whether any assistance programmes apply.